Nasus Pharma opens at $8, IPO priced at $8 per share

Nasus Pharma (NSRX) priced 1.25M shares at $8.00 in initial public offering. The company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine program, including, manufacturing scale-up and additional Phase 2 studies, and the remainder for general and administrative corporate purposes, including working capital, and capital expenditures. Laidlaw and Craft Capital Management are acting as joint book running managers for the offering.